Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright
TheFly, 10 January 2020
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.
Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.
RELATED:
